hrp0095p2-221 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Clinical and laboratory assessment of children with central precocious puberty during and after stoppage of treatment with gonadotropin-releasing hormone agonist

El-Hawary Amany , Elsharkawy Ashraf , Abdelrazik Wafaa , Aboelenin Hadil

Central precocious puberty (CPP) caused by early maturation of the hypothalamic–pituitary–gonadal axis, resulting in early appearance of secondary sexual characteristics That affects children’s normal life and their adulthood’s final height. GnRH agonist therapy inhibits stimulating effects of endogenous GnRH by desensitizing hypophyseal gonadotropic cells and thus acceleration in bone maturation and early puberty is suppressed. So the aim of this longi...

hrp0097p2-223 | Growth and Syndromes | ESPE2023

The Impact of Different Karyotypes on the Response to Growth Hormone Therapy in Girls with Turner Syndrome

El-Hawary Amany , Elsharkawy Ashraf , Gaber Amira , Salem Nanees

Background: Short stature is the most common clinical feature in patients with Turner syndrome (TS). The relation of different karyotyping to growth hormone (GH) level in provocation tests or to the response to GH therapy is debatable.Aim: to study the impact of different karyotypes on the GH level in provocation tests and on the response to GH therapy among a cohort of Egyptian girls with TS.<stro...